NCT03387085
|
Phase Ib/II |
ETBX-051
Aldoxorubicin
ETBX-061
Cisplatin
Cyclophosphamide
GI-4000
Bevacizumab
ALT-803
Fluorouracil
ETBX-011
Oxaliplatin
Capecitabine
Leucovorin
GI-6301
nab-paclitaxel
Avelumab
GI-6207
|
QUILT-3.067: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. |
Recruiting |
NCT03136406
|
Phase Ib/II |
GI-4000
Leucovorin
Avelumab
nab-paclitaxel
Bevacizumab
Cyclophosphamide
Capecitabine
Oxaliplatin
Fluorouracil
ETBX-011
ALT-803
|
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Active, not recruiting |
NCT03387098
|
Phase Ib/II |
GI-4000
Leucovorin
nab-paclitaxel
Bevacizumab
Avelumab
ALT-803
Fluorouracil
ETBX-011
Oxaliplatin
Aldoxorubicin
Capecitabine
Cyclophosphamide
|
QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Active, not recruiting |
NCT03387111
|
Phase Ib/II |
Capecitabine
nab-paclitaxel
Leucovorin
GI-6301
GI-6207
Avelumab
ETBX-021
ETBX-051
ETBX-061
Aldoxorubicin
Cisplatin
Cyclophosphamide
Bevacizumab
Necitumumab
GI-4000
Cetuximab
ALT-803
Fluorouracil
ETBX-011
|
Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy |
Recruiting |